Recent research have centered on the convergence of GLP-1|GIP|glucagon receptor stimulant therapies and dopamine communication. While GCGR activators are widely employed for managing type 2 diabetes, their emerging consequences on motivation circuits, specifically mediated by dopamine pathways, are attracting substantial attention. This article pro